Aspen Holdings News

Aspen launches novel ARV Combination: Set to further improve treatment options

Johannesburg: Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of EmdoltenTM, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option. EmdoltenTM, a once a day triple combination tablet therapy in the form of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, is positioned to become a preferred first line ARV and will…

Read More

Aspen’s participation in the 2018 Investment Conference

Sandton – Aspen welcomes President Ramaphosa’s inaugural Investment Conference, aimed at positioning South Africa as a preferred investment destination and at establishing a more predictable and stable investment environment in our country. Amongst other initiatives, this includes facilitating the ease of doing business and reducing unnecessary regulatory burden in the South African pharmaceutical sector. These…

Read More

Aspen supports the World Thrombosis Day campaign

Aspen remains committed to the World Thrombosis Day campaign to raise awareness of thrombosis as an urgent and growing public health problem. PARIS, FRANCE – Aspen has reinforced its commitment to fight thrombosis worldwide through its long-standing partnership with the International Society on Thrombosis and Haemostasis (ISTH) World Thrombosis Day (WTD) campaign. This initiative aims to…

Read More

Aspen’s revenue increases to R42.6 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, has announced today, in conjunction with the announcement of its annual results for the year ended 30 June 2018, that it has concluded an agreement to divest of its global Nutritional Business to the Lactalis Group. Download (PDF 183KB)

Read More

Aspen’s continued commitment to Mandela Day

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, is, for the eighth consecutive year, participating in Mandela Day through activities hosted by its businesses spanning 6 continents. Stephen Saad, Aspen Group Chief Executive said, “We heeded the Mandela Day call for the first time in 2011 and we…

Read More

Realising Joost’s dream for MND care

Through public private partnership the Gauteng Department of Health and Chris Hani Baragwanath Academic Hospital (CHBAH) gave recognition to their Motor Neuron Disease (MND) clinic as a center of excellence to intensify its health care services. This is in response to a  desperate need to offer special care to patients who are suffering from this…

Read More

Aspen opens R1 billion high containment facility

Port Elizabeth – JSE Limited-listed Aspen Pharmacare (APN), South Africa’s largest pharmaceutical company, officially opened its R1 billion Port Elizabeth-based high containment facility earlier today. Stephen Saad, Aspen Group Chief Executive said, “Aspen continues its evolution into a global specialty manufacturer of niche products requiring complex technologies. The high potency manufacturing facility we are opening…

Read More

Aspen presented with the Ubuntu Economic Diplomacy (Africa) Award

Cape Town – JSE Limited-listed Aspen Pharmacare (APN), South Africa’s largest pharmaceutical company, was presented with the Economic Diplomacy (Africa) Award by the South African Government at the prestigious 4th annual Ubuntu Awards, held in Cape Town on 22 March 2018. Accepting the award from Lindiwe Sisulu, Minister of International Relations and Cooperations (“Dirco”) on…

Read More

CNBC Exclusive with Aspen CEO Stephen Saad

Aspen Pharmacare billionaire Steven Saad opens up with the inside story of the fall of his shares. Exclusive on CNBC Africa first in business worldwide. CNBC Exclusive with Aspen CEO Stephen Saad from Aspen Pharmacare Pty Limited on Vimeo.

Read More